Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The "optional cross-over design" for randomized controlled trials

E Ernst1, K L Resch

  • 1Centre for Complementary Health Studies, University of Exeter Postgraduate Medical School, UK.

Fundamental & Clinical Pharmacology
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The "Hoddle Muddle": using faith healers and other complementary therapists in sports medicine.

British journal of sports medicine·1998
Same author

Does post-exercise massage treatment reduce delayed onset muscle soreness? A systematic review.

British journal of sports medicine·1998
Same author

The rise and fall of complementary medicine.

Journal of the Royal Society of Medicine·1998
Same author

The prevalence of complementary/alternative medicine in cancer: a systematic review.

Cancer·1998
Same author

Does moderate alcohol consumption affect fertility? Follow up study among couples planning first pregnancy.

BMJ (Clinical research ed.)·1998
Same author

[Phytotherapy. 1. Use in diseases of the locomotor system].

Fortschritte der Medizin·1998
Same journal

Glucagon-Like Peptide-1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms.

Fundamental & clinical pharmacology·2026
Same journal

TAAR1-Associated Trace Amines for Cutaneous Nociceptive Blockade in Rats.

Fundamental & clinical pharmacology·2026
Same journal

Synergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia-Reperfusion Injury.

Fundamental & clinical pharmacology·2026
Same journal

Probucol Exerts Anticancer Effects on SW480 Human Colorectal Cancer Cells via Modulation of Apoptosis- and Angiogenesis-Related Proteins.

Fundamental & clinical pharmacology·2026
Same journal

Nebivolol Protects the Thoracic and Abdominal Aorta and Their Perivascular Adipose Tissue From the Differential Detrimental Effects of Obesity.

Fundamental & clinical pharmacology·2026
Same journal

Monitoring of Clinics That Use Direct-to-Consumer Advertising for Off-Label Ketamine in the New York Metropolitan Area: A Cross-Sectional Systematic Web Search.

Fundamental & clinical pharmacology·2026
See all related articles

The optional cross-over design allows randomized controlled trials (RCTs) to use patient-reported outcomes. This flexible RCT method is ideal when subjective patient experiences are key endpoints.

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Patient-Reported Outcomes

Background:

  • Randomized controlled trials (RCTs) often rely on objective endpoints.
  • Subjective patient experiences are crucial in many therapeutic areas but difficult to quantify.
  • Existing RCT designs may not adequately capture patient-reported treatment success.

Purpose of the Study:

  • To introduce and describe the "optional cross-over design" for RCTs.
  • To provide a framework for incorporating subjective patient endpoints in clinical trials.
  • To offer a flexible RCT methodology for situations lacking hard endpoints.

Main Methods:

  • Patients are randomized to active medication or placebo in Phase I.
  • Patients can opt to switch treatment arms if therapy is perceived as unsuccessful (optional cross-over).

Related Experiment Videos

  • Phase II continues treatment, accommodating optional cross-overs, with potential for further cross-over points.

    • Main Results:

    • Statistical evaluation at trial end assesses treatment arm distribution.
    • High percentages in the active arm suggest optimal treatment success.
    • A 50:50 distribution indicates an ineffective treatment.

    Conclusions:

    • The optional cross-over design is suitable for RCTs prioritizing patient subjective experience.
    • This design facilitates the use of patient-reported outcomes as primary endpoints.
    • It offers a pragmatic approach to clinical trials where objective measures are limited.